Further studies are warranted to determine whether the MAPS pathway contributes to the intercellular transmission of misfolded polypeptides under aging or disease conditions, which if proven to be true, might offer a completely new perspective to develop unprecedented therapeutic schemes for diseases such as Parkinson’s disease and Alzheimer’s disease. Here, C3orf62 is linked to early-onset autosomal dominant Alzheimer disease.